Communiqués Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/01/2026			Varia. 5j.	Varia. 1 janv.
2,650 ^USD	+0,76%		-.--%	+1,92%

03/02	Pyxis Oncology, Inc. annonce des changements à la direction générale, effectifs au 3 février 2026	CI
28/01	Xenotherapeutics Inc finalise l'acquisition de Repare Therapeutics Inc. (NasdaqGS:RPTX) auprès de BVF Partners L.P., Blue Owl Healthcare Opportunities, OrbiMed Advisors LLC et d'autres	CI

Communiqués

16/01	Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.	BU
24/12	Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration	BU
20/11	Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.	BU
14/11	Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.	BU
13/10/25	Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	BU
08/08/25	Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results	BU
15/07/25	Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib	BU
13/05/25	Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results	BU
01/05/25	Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics	BU
28/04/25	Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025	AQ
25/04/25	Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025	BU
31/03/25	Repare Therapeutics Announces Leadership Transitions	BU
10/03/25	Repare Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
07/03/25	Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03/03/25	Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results	BU
09/01/25	Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions	BU
12/12/24	Repare Therapeutics : Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Form 8 K	PU
12/12/24	Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial	BU
10/12/24	Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial	BU
12/11/24	Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib	BU
07/11/24	Repare Therapeutics : Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results Form 8 K	PU
07/11/24	Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results	BU
23/10/24	Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial	BU
15/10/24	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol ATPase Inhibitor	AQ
14/10/24	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor	BU